- Home
- CET vs RCKT Comparison
CET vs RCKT Comparison
Compare CET & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CET
- RCKT
- Stock Information
- Founded
- CET 1929
- RCKT 1999
- Country
- CET United States
- RCKT United States
- Employees
- CET N/A
- RCKT N/A
- Industry
- CET Finance/Investors Services
- RCKT Biotechnology: Pharmaceutical Preparations
- Sector
- CET Finance
- RCKT Health Care
- Exchange
- CET Nasdaq
- RCKT Nasdaq
- Market Cap
- CET 1.3B
- RCKT 1.4B
- IPO Year
- CET N/A
- RCKT N/A
- Fundamental
- Price
- CET $46.84
- RCKT $14.11
- Analyst Decision
- CET
- RCKT Strong Buy
- Analyst Count
- CET 0
- RCKT 10
- Target Price
- CET N/A
- RCKT $52.40
- AVG Volume (30 Days)
- CET 31.2K
- RCKT 947.0K
- Earning Date
- CET 01-01-0001
- RCKT 11-07-2024
- Dividend Yield
- CET 4.95%
- RCKT N/A
- EPS Growth
- CET 64.57
- RCKT N/A
- EPS
- CET 10.32
- RCKT N/A
- Revenue
- CET $23,374,777.00
- RCKT N/A
- Revenue This Year
- CET N/A
- RCKT N/A
- Revenue Next Year
- CET N/A
- RCKT $411.05
- P/E Ratio
- CET $4.51
- RCKT N/A
- Revenue Growth
- CET 41.71
- RCKT N/A
- 52 Week Low
- CET $36.07
- RCKT $12.62
- 52 Week High
- CET $49.51
- RCKT $32.53
- Technical
- Relative Strength Index (RSI)
- CET 47.39
- RCKT 37.41
- Support Level
- CET $46.02
- RCKT $12.62
- Resistance Level
- CET $47.25
- RCKT $17.83
- Average True Range (ATR)
- CET 0.65
- RCKT 1.03
- MACD
- CET -0.27
- RCKT -0.28
- Stochastic Oscillator
- CET 23.43
- RCKT 26.85
About CET Central Securities Corporation
Central Securities Corp is a non-diversified closed-end management investment company. Its investment objective is long-term growth of capital. The company invests in common stocks, bonds, convertible bonds, preferred stocks, convertible preferred stocks, warrants, options real estate, or short-term obligations of governments, banks, and corporations.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis.